Advanced Medical Solutions Group Regulatory News (AMS)

Advanced Medical Solutions Group plc

("AMS" or the "Group")

CE approval for cyanoacrylate-based device for hernia mesh fixation

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces that it has received CE approval for a newly developed cyanoacrylate adhesive device for hernia mesh fixation - LiquiBand® Fix 8™.

The LiquiBand® Fix 8™device can accurately deliver individual drops of cyanoacrylate adhesive internally within the body, giving the surgeon precision and control for the first time. The accurate, laparoscopic application of adhesives to attach hernia meshes is expected to reduce surgical complications, in particular the potential pain associated with the use of tacks and staples, thereby improving the patient experience and reducing healthcare costs overall. The new device augments AMS's existing LiquiBand® range of topical tissue adhesive products which are designed for precise and controlled wound closure.

LiquiBand® Fix 8™ will be marketed and distributed in the second half of 2014 by the Group's direct sales teams in the UK and Germany and through various distributor partners across the EU. AMS is currently entering into a number of clinical evaluations.

Chris Meredith, Chief Executive Officer of AMS commented:

"We are very pleased with this approval and the early interest in our new product. LiquiBand® Fix 8™ will benefit both patients and healthcare providers and is an important part of our strategy to increase our penetration of the Operating Theatre segment of the market. We believe that this innovation from our R&D pipeline will lead to further opportunities for this kind of application and to the development of a wider market for the use of adhesives internally."

- ends -

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com 

Founded in 1991, AMS is a leader in the development and manufacture of innovative and technologically advanced products for the US$21 billion global wound care and wound closure market. Through a mix of organic development and a number of acquisitions, AMS now has a wide range of products based on technologies that include alginates, silver alginates, foams, collagens, cyanoacrylate adhesives and sutures.

AMS manufactures wound care products for an extensive list of Original Equipment Manufacturer ("OEM") customers around the world, but the majority of the Group's revenues now come from its own brands - ActivHeal® wound care products in the UK to the NHS, LiquiBand® cyanoacrylate products primarily in the UK, Europe and the USA, and RESORBA® sutures and collagen wound care products primarily in Europe. AMS developes innovative products from its R&D pipeline which it commercialises globally through partnerships with its OEM customers.

AMS's products are sold globally via a network of regional or multinational partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia.

With 450 employees operating under four distinct business units that match its multiple products and routes-to-market (Branded Direct, Branded Distributed, OEM and Bulk Materials), AMS's products are manufactured from two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic